HC Royalty Discusses the Biotech Financing Market on CNBC’s The Strategy Session

CNBC | By Gennine Kelly

Biotech companies are addicted to capital like “crack addicts are addicted to crack," because of the $1 billion-plus price tag that it takes to bring a drug to market, Gregory Brown, founder and managing director of Cowen Healthcare Royalty Partners, told CNBC Monday.